Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about a recent article by David J. Kuter et al. published in NEJM, adding:
“Exciting new data in ITP treatment : a phase 2 NEJM Group study found that mezagitamab, a CD38-targeting antibody, produced rapid and sustained platelet responses, with the highest dose showing a platelet response in 91% of patients by week 16 and a safety profile similar to placebo.
Why this matters: ITP remains an area of major unmet need, and this therapy may represent a true shift from symptom control toward disease modification by targeting the immune cells driving platelet destruction.
If confirmed in phase 3, mezagitamab could meaningfully change the treatment landscape for patients who do not respond well to current options.
600 mg dose achieving a platelet response in 91% of patients by week 16 and a tolerability profile comparable to placebo.
This is especially important in ITP, where many patients still have limited durable responses to existing therapies.
By targeting CD38-expressing immune cells, mezagitamab may offer a more disease-modifying approach rather than just temporary platelet support.”
Title: A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
Authors: David J. Kuter, Katsuhiro Miura, Andrea Patriarca, Dražen Pulanić, Atanas Radinoff, Katya Sapunarova, Antonia Syrigou, Renchi Yang, Van Anh Nguyen, Emily Skelton, Scarlett Wang, Donald L. Yee, Parth Patwari
Stay updated on all scientific advances with Hemostasis Today.
-
May 18, 2026, 14:47Ting Yuan: Understanding the Complexity Behind Repeated IVF Failure
-
May 18, 2026, 14:33Global Resolution on Advancing Comprehensive Care and Health Equity for People with Bleeding Disorders Worldwide at the 79th WHA – WFH
-
May 18, 2026, 14:25Salih Ehsan: Key Diagnostic Clues in Thalassemia Minor
-
May 18, 2026, 14:02Matteo Foschi: A Global Gathering for Stroke Innovation and Research at ESOC 2026
-
May 18, 2026, 14:01Who is the NBA? – Haemophilia Foundation Australia
-
May 18, 2026, 14:00Julie Makani: Partnership between Tanzania and the USA – Health Sciences
-
May 18, 2026, 13:58Alejandro González Veliz: Cardiology Enters the Era of Inflammation
-
May 18, 2026, 13:50Arshad-Ali Auhammad: Celebrating Youth Leadership in the Global Bleeding Disorders Community
-
May 18, 2026, 13:36Zain Khalpey: In Cardiovascular Medicine Flow Is Everything